Canada Life
ALLO icon

Canada Life’s Allogene Therapeutics ALLO Stock Holding History

Canada Life’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$158K Buy
64,970
+14,019
+28% +$28.1K ﹤0.01% 1631
2025
Q4 		$69K Buy
50,951
+11,221
+28% +$14.8K ﹤0.01% 1759
2025
Q3 		$50K Buy
39,730
+8,519
+27% +$10.2K ﹤0.01% 1816
2025
Q2 		$35K Buy
31,211
+18,314
+142% +$24.3K ﹤0.01% 1854
2025
Q1 		$19K Sell
12,897
-7,528
-37% -$14.2K ﹤0.01% 1942
2024
Q4 		$44K Buy
20,425
+241
+1% +$594 ﹤0.01% 1898
2024
Q3 		$57K Sell
20,184
-3,908
-16% -$10.4K ﹤0.01% 1938
2024
Q2 		$56K Buy
24,092
+6,342
+36% +$18.7K ﹤0.01% 1955
2024
Q1 		$79K Buy
17,750
+8,162
+85% +$34.1K ﹤0.01% 1968
2023
Q4 		$31K Sell
9,588
-2,583
-21% -$7.33K ﹤0.01% 2070
2023
Q3 		$39K Hold
12,171
– – ﹤0.01% 2073
2023
Q2 		$61K Buy
12,171
+3,344
+38% +$18.1K ﹤0.01% 1983
2023
Q1 		$43K Buy
8,827
+1,826
+26% +$11.7K ﹤0.01% 2089
2022
Q4 		$44K Buy
7,001
+777
+12% +$7.19K ﹤0.01% 2094
2022
Q3 		$67K Buy
6,224
+484
+8% +$6.58K ﹤0.01% 2055
2022
Q2 		$66K Buy
5,740
+503
+10% +$4.46K ﹤0.01% 1994
2022
Q1 		$50K Buy
5,237
+450
+9% +$4.69K ﹤0.01% 2153
2021
Q4 		$72K Buy
4,787
+439
+10% +$7.75K ﹤0.01% 2081
2021
Q3 		$112K Hold
4,348
– – ﹤0.01% 2032
2021
Q2 		$113K Sell
4,348
-201
-4% -$5.73K ﹤0.01% 2056
2021
Q1 		$159K Buy
4,549
+935
+26% +$31.5K ﹤0.01% 2002
2020
Q4 		$91K Hold
3,614
– – ﹤0.01% 2134
2020
Q3 		$136K Hold
3,614
– – ﹤0.01% 1974
2020
Q2 		$154K Buy
3,614
+1,987
+122% +$71.9K ﹤0.01% 1958
2020
Q1 		$32K Hold
1,627
– – ﹤0.01% 2254
2019
Q4 		$42K Buy
+1,627
New +$44.8K ﹤0.01% 2317
2019
Q3 		– Sell
-3,067
Closed -$82K – 1151
2019
Q2 		$82K Buy
+3,067
New +$85.5K ﹤0.01% 2284

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Canada Life's ALLO Position: Q1 2026 in Review

Canada Life increased its Allogene Therapeutics (ALLO) stake by 28% in Q1 2026, buying an estimated $28.1K and bringing the position to 64,970 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #1631.

Canada Life first reported a position in ALLO in Q2 2019 and has held it in 27 quarters since. The position peaked at $159K in Q1 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Canada Life held 64,970 shares of Allogene Therapeutics worth $158K as of Q1 2026.
  • Canada Life bought 14,019 Allogene Therapeutics shares in Q1 2026, an estimated $28.1K.
  • Allogene Therapeutics made up ﹤0.01% of Canada Life's portfolio in Q1 2026, its #1631 holding.
  • Canada Life first reported a position in Allogene Therapeutics in Q2 2019 and has held it in 27 quarters since.
  • Canada Life's Allogene Therapeutics position peaked at $159K in Q1 2021.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.